Wellbutrin
Chronic Kidney Diseases
Stony Brook UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Chronic Kidney Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Simethicone Alfredo Di Leo | Phase 4 | BB |
DABIGATRAN ETEXILATE Irina Ermolaeva | Phase 4 | BB |
CEFADROXIL ANHYDROUS Mayo Clinic | Phase 4 | BB |
CITRIC ACID MONOHYDRATE Alfredo Di Leo | Phase 4 | BB |
MACROGOLS Alfredo Di Leo | Phase 4 | BB |
View all 21 →
Same molecule, other indications
Wellbutrin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →